Elliott Levy

Elliott has served as a member of board of directors since 2021.

Elliott has been Senior Vice President of Global Development and R&D Strategy and Operations at Amgen where he was responsible for managing and executing Amgen’s R&D strategy and drug development process. Previously, Elliott spent 17 years at Bristol-Myers Squibb (BMS) where he was Senior Vice President and Head of Specialty Development and held a range of senior positions in BMS’s research and development group. Prior to joining BMS, Elliott was a member of the Renal Division at Brigham and Women's Hospital, where he was an investigator in federally-sponsored outcomes research and industry-sponsored clinical trials. Elliott currently serves as a director for Omega Therapeutics and serves as CEO of Intrepid Alliance, a non-profit whose objective is to facilitate the development of small molecule therapeutics for future pandemic agents. He previously served as Board Chair of TransCelerate BioPharma.

Dr. Levy has 24 years’ experience in the clinical development and regulatory approval of investigational medicines in the biopharmaceutical industry. He received his M.D. from the Yale School of Medicine, where he was Chief Medical Resident focusing on internal medicine and nephrology and completed fellowship training in clinical research through the Robert Wood Johnson Clinical Scholars program.